TrialPath
Recruiting

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

NCT06118723 · Erasmus Medical Center
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
The SUPRAMAX-study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
About this study
This is an international, multicenter, prospective, observational, 2-arm cohort study (registration: clinicaltrials.gov ID number TBA). Eligible patients are operated with supramaximal resection versus maximal resection with a 1:3 ratio with a sequential computer-generated random number as subject ID. Intraoperative mapping techniques and/or surgical adjuncts can be used in both treatment arms to ensure the safety of the resection (to minimize the risk of postoperative deficits). Supramaximal resection is defined as 0 cm3 CE tumor and 5 cm3 or less NCE tumor, whereas maximal resection is defined as 0 cm3 CE tumor and \>5 cm3 NCE tumor (in line with the updated RANO criteria). Study patients are allocated to either the supramaximal or maximal safe resection group and will undergo evaluation at presentation (baseline) and during the follow-up period at 6 weeks, 3 months, and 6 months postoperatively. Motor function will be evaluated using the NIHSS (National Institute of Health Stroke Scale) scale. Language function will be evaluated using a standard neurolinguistic test-battery consisting of the Aphasia Bedside Check (ABC), Shortened Token test, Verbal fluency, Picture description and Object naming. Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). Patient functioning with be assessed with the Karnofsky Performance Scale (KPS) and the ASA (American Society of Anesthesiologists) physical status classification system. Health-related quality of life (HRQoL) will be assessed with the EORTC QLQ C30, EORTC QLQ BN20 and EQ 5D questionnaires. Overall survival and progression-free survival will be assessed. We expect to complete patient inclusion in 4 years. The estimated duration of the study (including follow-up) will be 5 years. The primary study objective is to evaluate the safety and efficacy of supramaximal resection versus safe maximal resection in HGG patients as measured by overall survival (OS) and postoperative NIHSS deterioration. Secondary study objectives are to evaluate extent of resection of CE and NCE tumor, quality of life, progression-free survival (PFS), onco-functional outcome (OFO), and SAEs after SMR or maximal safe resections as measured by volumetric analyses of contrast-enhanced MRI images with gadolinium combined with FLAIR images, tumor progression on MRI scans, quality of life questionnaires (EORTC QLQ C30, EORTC QLQ BN20, EQ 5D), combining postoperative residual volume with NIHSS outcomes, and recording SAEs respectively. Patients will be recruited from the neurosurgical or neurological outpatient clinic or through referral from general hospitals of the participating neurosurgical hospitals, located in Europe and the United States. The study is carried out by centers from the ENCRAM Consortium.
Eligibility criteria
Inclusion Criteria: 1. Age ≥18 years and ≤90 years 2. Tumor diagnosed as HGG (WHO grade III/IV) on MRI as assessed by the neurosurgeon 3. Written informed consent Exclusion Criteria: 1. Tumors of the cerebellum, brainstem or midline 2. Multifocal contrast enhancing lesions 3. Medical reasons precluding MRI (e.g. pacemaker) 4. Inability to give written informed consent 5. Secondary high-grade glioma due to malignant transformation from low-grade glioma 6. Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin
Study design
Enrollment target: 784 participants
Age groups: adult, older_adult
Timeline
Starts: 2022-01-01
Estimated completion: 2028-01-01
Last updated: 2024-02-22
Interventions
Procedure: Supramaximal resectionProcedure: Maximal safe resection
Primary outcomes
  • • Overall survival (Up to 5 years postoperatively)
  • • Neurological morbidity at 6 weeks (6 weeks postoperatively)
Sponsor
Jasper Gerritsen · other
With: Haaglanden Medical Centre, Universitaire Ziekenhuizen KU Leuven, University Hospital Heidelberg, Technical University of Munich, Insel Gruppe AG, University Hospital Bern, Massachusetts General Hospital, University of California, San Francisco
Contacts & investigators
ContactJasper Gerritsen, MD PhD · contact · j.gerritsen@erasmusmc.nl · +31107036130
ContactArnaud Vincent, MD PhD · contact · a.vincent@erasmusmc.nl · +31107034211
InvestigatorJasper Gerritsen, MD PhD · principal_investigator, Erasmus Medical Center
All locations (8)
University of California, San Francisco (UCSF)Recruiting
San Francisco, California, United States
Massachusetts General HospitalRecruiting
Boston, Massachusetts, United States
University Hospitals LeuvenRecruiting
Leuven, Belgium
Universitätsklinikum HeidelbergRecruiting
Heidelberg, Baden-Wurttemberg, Germany
Technical University MunichNot Yet Recruiting
Munich, Bavaria, Germany
Erasmus Medical CenterRecruiting
Rotterdam, South Holland, Netherlands
Haaglanden Medical CentreRecruiting
The Hague, South Holland, Netherlands
Inselspital Universitätsspital BernNot Yet Recruiting
Bern, Switzerland
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) · TrialPath